A Randomized Phase II Trial of MEK Inhibitor Selumetinib (AZD6244) Combined Continuously or Sequentially With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Patients With Advanced Biliary Cancer
This is a phase II study (the second stage of testing a new drug or new drug combinations)
to see how useful two different schedules of study drug selumetinib with cisplatin and
gemcitabine are compared to cisplatin and gemticabine alone in patients with biliary cancer.
Selumetinib, an oral drug which plays an important role in the regulation of cell growth
(MEK 1/2 inhibitor) has been shown to shrink tumours in patients with biliary cancer and
other types of human cancers. Selumetinib has also been shown to shrink tumours when given
in combination with cisplatin and gemcitabine in research studies done in animals and in
some patients with biliary tract cancer. Cisplatin and gemcitabine are intravenous drugs
that work by damaging DNA in tumour cells so that they are unable to grow and divide.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society